EXEL News and Press, Exelixis Inc. From 07/17/23

2023-07-17 17:51:33 ET Summary Markets roared ahead by over two percent on the week on the back of softer than expected June CPI and PPI reports. Investors are signaling they believe the Federal Reserve will achieve the much hoped for "soft landing." There are two good reasons...

2023-06-26 13:51:44 ET Summary Markets have performed well so far in 2023, based on the major indices, but the rally has lacked breadth and been driven primarily by a few mega-cap stocks like Apple. The Federal Reserve's most aggressive monetary tightening since the early 80s is f...

Based on Preliminary Results, Farallon Director Candidates Tom Heyman, Dave Johnson and Bob Oliver Have Each Been Elected Expects Exelixis' Board to Welcome the New Directors and Embrace Fresh Perspectives to Help Improve Lagging Performance Thanks Fellow Shareholders for Their Su...

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in June: William Blair 43 rd Annual...

2023-05-28 05:49:02 ET Summary Revenue-generating products like Cabometyx and strategic partnerships with industry leaders, such as Genentech, contribute to Exelixis' impressive financial performance and market presence. Exelixis' robust pipeline, featuring innovative therapies li...

2023-05-24 09:53:00 ET There are reasons to be wary of the stock market right now. Chief among them is the fact that the economy continues to be somewhat uncertain, making it difficult to predict how things will develop in the next year. But the short-term prospects of equities are almost a...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-05-16 16:59:34 ET Summary Today, we circle back on mid-cap oncology name Exelixis, whose shares have largely been rangebound for years despite consistent revenue growth and a fortress balance sheet. The company has recently drawn the attention of an activist fund that has won...

2023-05-10 02:00:28 ET Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q1 2023 Earnings Call Transcript

2023-05-09 21:12:07 ET Exelixis, Inc. (EXEL) Q1 2023 Earnings Conference Call May 09, 2023 05:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO P.J. Haley - EVP, Commercial Dana ...